Dr. Stephen Bagley, MD
Claim this profileUniversity of Pennsylvania
Studies Brain Tumor
Studies Benign Glioma
8 reported clinical trials
14 drugs studied
Area of expertise
1Brain Tumor
IDH positive
1p/19q codeletion positive
H3 K27M positive
2Benign Glioma
IDH positive
H3 K27M positive
1p/19q co-deletion positive
Affiliated Hospitals
Clinical Trials Stephen Bagley, MD is currently running
CAR T-cell Therapy
for Glioblastoma
This is an open-label phase 1 study to assess the safety and feasibility of autologous T cells co-expressing two CARs targeting the cryptic EGFR and IL13Ra2 (referred to as "CART-EGFR-IL13Ra2 cells") in patients with EGFR-amplified glioblastoma, IDH-wildtype that has recurred following prior radiotherapy.
Recruiting1 award Phase 1
ONC201
for Brain Tumor
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with ONC201 following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.
Recruiting1 award Phase 3
More about Stephen Bagley, MD
Clinical Trial Related7 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Stephen Bagley, MD has experience with
- ONC201
- All-trans Retinoic Acid
- Retifanlimab
- CART-EGFR-IL13Ra2 Cells
- Abemaciclib
- Brain Surgery
Breakdown of trials Stephen Bagley, MD has run
Brain Tumor
Benign Glioma
Glioblastoma
Oligodendroglioma-Astrocytoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Stephen Bagley, MD specialize in?
Stephen Bagley, MD focuses on Brain Tumor and Benign Glioma. In particular, much of their work with Brain Tumor has involved IDH positive patients, or patients who are 1p/19q codeletion positive.
Is Stephen Bagley, MD currently recruiting for clinical trials?
Yes, Stephen Bagley, MD is currently recruiting for 3 clinical trials in Philadelphia Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Stephen Bagley, MD has studied deeply?
Yes, Stephen Bagley, MD has studied treatments such as ONC201, All-trans retinoic acid, Retifanlimab.
What is the best way to schedule an appointment with Stephen Bagley, MD?
Apply for one of the trials that Stephen Bagley, MD is conducting.
What is the office address of Stephen Bagley, MD?
The office of Stephen Bagley, MD is located at: University of Pennsylvania, Philadelphia, Pennsylvania 19104 United States. This is the address for their practice at the University of Pennsylvania.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.